Sökning: id:"swepub:oai:DiVA.org:uu-133819" >
Molecular monitorin...
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib
-
- Olsson-Strömberg, Ulla (författare)
- Uppsala universitet,Medicin,Hematologi
-
- Hermansson, Monica (författare)
- Uppsala universitet,Institutionen för genetik och patologi
-
Lundan, Tuija (författare)
-
visa fler...
-
Ohm, Anne-Charlotte (författare)
-
- Engdahl, Ida (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Höglund, Martin (författare)
- Uppsala universitet,Medicin,Hematologi
-
- Simonsson, Bengt (författare)
- Uppsala universitet,Medicin,Hematologi
-
Porkka, Kimmo (författare)
-
- Barbany, Gisela (författare)
- Karolinska Institutet,Uppsala universitet,Institutionen för genetik och patologi
-
visa färre...
-
(creator_code:org_t)
- 2010-07-26
- 2010
- Engelska.
-
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 85:5, s. 399-404
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- As a result of the excellent responses achieved in chronic phase chronic myeloid leukemia since the introduction of imatinib, sensitive techniques such as reverse transcriptase real-time PCR are warranted to monitor patients receiving tyrosine kinase inhibitors (TKI). Our objective was to determine the value of molecular monitoring Ph-positive leukemias under dasatinib treatment. We used real-time PCR and ABL1 kinase domain sequencing on sequential samples from 11 patients with Philadelphia-positive leukemias who received dasatinib. We were able to detect pre-existing mutations in the kinase domain of BCR-ABL1 in four patients, particularly in patients with high BCR-ABL1 transcript levels. Most mutations disappeared with dasatinib, however, in five patients a clone with T315I appeared during dasatinib treatment. We conclude that sensitive molecular monitoring with real-time PCR for BCR-ABL1 transcripts and mutation screening of the ABL1 kinase domain of patients with Philadelphia-positive leukemias are valuable for patient management, however, mutation findings should be interpreted with caution, as mutant clones not always behave in vivo as predicted by in vitro assays.
Nyckelord
- chronic myeloid leukemia
- mutation
- molecular monitoring
- MEDICINE
- MEDICIN
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas